Cassidy J, Macfarlane D K
Clinical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Cancer Nurs. 1991 Jun;14(3):124-31.
Although advances have been made in the treatment of a number of cancers, no standard effective treatment exists for many forms of the disease. To answer remaining questions about cancer therapy, patients are encouraged to enter clinical trials that test new therapies or combinations of therapies. These trials take place not only in cancer centers and large university hospitals, but also in community hospitals and private offices throughout the country. The nurse can be an active participant in these trials as both the patient advocate and the liaison between the patient and the physician or the nurse researcher responsible for conducting the clinical investigation. Each protocol contains specific guidelines that include eligibility requirements, detailed treatment regimens, patient evaluations, and data collection schedules. The regulatory issues or Institutional Review Board (IRB) approval, informed consent, toxicity reporting, and maintenance of accurate records for investigational drug accountability are also part of the research process. A nurse who is well informed on these issues is an asset to the successful completion of any clinical study.
尽管在多种癌症的治疗方面已取得进展,但对于许多形式的癌症,尚无标准有效的治疗方法。为了回答有关癌症治疗的剩余问题,鼓励患者参加测试新疗法或联合疗法的临床试验。这些试验不仅在癌症中心和大型大学医院进行,也在全国各地的社区医院和私人诊所开展。护士既可以作为患者的倡导者,也可以作为患者与负责进行临床研究的医生或护士研究人员之间的联络人,积极参与这些试验。每个方案都包含特定的指导原则,包括入选标准、详细的治疗方案、患者评估和数据收集时间表。监管问题或机构审查委员会(IRB)的批准、知情同意、毒性报告以及为研究药物问责制维护准确记录,也是研究过程的一部分。熟悉这些问题的护士对于任何临床研究的成功完成都是一项资产。